ArticleCureus2025
Endoscopic Management of Mirizzi Syndrome: Experience and Outcomes From a Tertiary Care Center in Mexico.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMirizzi syndrome (MS), an infrequent yet often delayed complication of cholelithiasis, poses diagnostic and therapeutic challenges stemming from its heterogeneous presentation, propensity for fistula formation, and distortion of anatomy within Calot's triangle. Although surgery remains a reference standard, this study examines therapeutic endoscopy as a safe and effective alternative within a Mexican tertiary center, where disease burden exceeds global estimates.
methodsWe conducted a retrospective, single-center observational study (January 2022-April 2025), identifying 16 patients with MS who underwent 22 endoscopic retrograde cholangiopancreatography (ERCP) procedures (out of 914 total). Data collected included demographics, Mirizzi classification (Csendes), endoscopic approach, technical (successful biliary decompression), and clinical outcomes (avoidance of surgery/complications, resolution of cholangitis). Statistical analyses included Fisher's exact tests for categorical variables, and Mann-Whitney U tests for continuous variables, with significance set at p < 0.05. Analyses followed established methodological standards.
resultsMS accounted for 2.4% of ERCP volume. Type I predominated (50%), followed by types IV, V, and III. The cohort's mean age fell in mid-adulthood, without apparent sex predilection. Overall, a technical success rate of 90.9% (20/22 procedures) was achieved, while clinical success was observed in 87.5% (14/16 patients). Non-surgical resolution was accomplished in 75.0% of types IV-V patients. In inferential analyses, procedure duration and fluoroscopy time, when stratified by Mirizzi type or presence of cholangitis (p ≥ 0.05), displayed no statistically significant differences. Advanced techniques, including SpyGlass cholangioscopy, showed a significant association with type IV MS (p = 0.0476). These results demonstrate an improvement as reported in previous success rates.
conclusionTherapeutic endoscopy is demonstrably effective and safe for select MS cases, effectively relieving biliary obstruction, and successfully managing cholangitis as either a bridge to eventual surgery or as a definitive standalone solution. Further studies are needed to establish standardized, evidence-based guidelines for endoscopic treatment of this complex syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.